- $1.86m
- $1.09m
- $4.69m
- 88
- 77
- 38
- 75
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.12 | ||
| Price to Tang. Book | 1.13 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.92% | ||
| Return on Equity | -16.84% | ||
| Operating Margin | -5.11% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.19 | 4.33 | 4.72 | 4.84 | 4.69 | n/a | n/a | 3.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +856.69 | +296.05 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Procyon Corporation operates through its subsidiaries AMERX Health Care Corporation (AMERX) and Sirius Medical Supply, Inc. (Sirius). AMERX develops and markets proprietary medical products used in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation and other skin problems. Its product lines include AMERX, AMERIGEL, HELIX3 Bioactive Collagen, EXTREMIT-EASE Compression Garment and Advantagen Surgical Collagen. AMERX markets a line of AMERIGEL advanced skin and wound care products made with Oakin, that promote healing in wound and problematic skin conditions, including AMERIGEL Hydrogel Wound Dressing, AMERIGEL Post Op Surgical Kits, AMERIGEL Saline Wound Wash, AMERIGEL Care Lotion, and AMERIGEL Barrier Lotion. HELIX3 is available in Collagen Powder and Collagen Matrix. Its wound care product includes AMERX Calcium Alginate Dressing, AMERX Foam Dressing, AMERX Gauze Dressing, AMERX Hyrdocolloid Dressing, and AMERX Wound Care Kits.
Directors
- Regina Anderson CHM (74)
- Justice Anderson PRE (44)
- James Anderson CFO (51)
- George Borak OTH (60)
- Steven Mccomas IND (54)
- Monica McCullough IND (50)
- Fred Suggs IND (74)
- Joseph Treshler IND (68)
- Last Annual
- June 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 19th, 1987
- Public Since
- December 11th, 1996
- No. of Shareholders
- 110
- No. of Employees
- 17
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 8,108,388
- Address
- 1300 S Highland Ave, CLEARWATER, 33756-6519
- Web
- https://procyoncorp.com/
- Phone
- +1 7274472998
- Auditors
- Ferlita, Walsh & Gonzalez, P.A.
Upcoming Events for PCYN
Similar to PCYN
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 22:46 UTC, shares in Procyon are trading at $0.29. This share price information is delayed by 15 minutes.
Shares in Procyon last closed at $0.29 and the price had moved by +17.6% over the past 365 days. In terms of relative price strength the Procyon share price has underperformed the S&P500 Index by -1.3% over the past year.
There is no consensus recommendation for this security.
Procyon does not currently pay a dividend.
Procyon does not currently pay a dividend.
Procyon does not currently pay a dividend.
To buy shares in Procyon you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.29, shares in Procyon had a market capitalisation of $2.38m.
Here are the trading details for Procyon:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PCYN
Based on an overall assessment of its quality, value and momentum Procyon is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Procyon. Over the past six months, its share price has outperformed the S&P500 Index by +56.15%.
As of the last closing price of $0.29, shares in Procyon were trading -19.33% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Procyon PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Procyon's management team is headed by:
- Regina Anderson - CHM
- Justice Anderson - PRE
- James Anderson - CFO
- George Borak - OTH
- Steven Mccomas - IND
- Monica McCullough - IND
- Fred Suggs - IND
- Joseph Treshler - IND